Malignancy in systemic lupus erythematosus: what have we learned?

Area of Science:

• Rheumatology
• Oncology
• Epidemiology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease associated with various health complications.
• Understanding cancer risk in SLE patients is crucial for proactive management and improved outcomes.

Purpose of the Study:

• To review current knowledge on cancer risk in patients with SLE over the past decade.
• To identify specific cancer types with increased incidence in SLE and explore potential underlying mechanisms.

Main Methods:

• Review of recent epidemiological data and clinical studies.
• Analysis of cancer incidence rates in SLE populations compared to the general population.
• Examination of factors including disease activity and medication exposure.

Main Results:

• A slightly increased risk for all cancers combined in SLE patients, driven by hematological malignancies (especially non-Hodgkin's lymphoma).
• Evidence suggests a moderately increased risk for lung cancer and potentially for hepatobiliary and vulvar/vaginal cancers.
• Increased cervical dysplasia risk in women with SLE, linked to both viral clearance and immunosuppressive medications (e.g., cyclophosphamide).

Conclusions:

• The precise mechanisms linking SLE to cancer risk remain largely unknown, with both disease activity and medication playing potential roles.
• SLE patients, particularly women, require vigilant screening for certain cancers, including cervical cancer, following established guidelines.